Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 5/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2986794 | 1.00 | SLC7A5 (0.56) | SLC7A5CA2CAMK2AESR1ESR2 | |
| Phenol SCHEMBL27420281 | 0.89 | CYP1A2 (0.50) | SLC7A5TRPV1POLBFOLH1FNTA | |
| Tyrosine SCHEMBL4908261 | 0.86 | SLC7A5 (0.69) | SLC7A5TRPV1 | |
| SCHEMBL5352342 | 0.85 | SLC7A5 (0.58) | SLC7A5CA2CAMK2AESR1ESR2 | |
| SCHEMBL157789 | 0.84 | CYP1A2 (0.57) | SLC7A5FOLH1 | |
| SCHEMBL157788 | 0.84 | CYP1A2 (0.57) | SLC7A5FOLH1 | |
| SCHEMBL2466759 | 0.84 | CYP1A2 (0.57) | SLC7A5FOLH1 | |
| SCHEMBL276571 | 0.83 | SLC7A5 (0.55) | SLC7A5CA2CAMK2AESR1ESR2 | |
| SCHEMBL38225 | 0.83 | SLC7A5 (0.55) | SLC7A5CA2CAMK2AESR1ESR2 | |
| SCHEMBL20494781 | 0.83 | SLC7A5 (0.55) | SLC7A5CA2CAMK2AESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427690-B2 | Multifunction “crown complexes” from amino acids and peptides for skin and hair restoration | BIODERM RESEARCH (US) | 2008-09-23 | — | — | US | claimed |
| US-20070099886-A1 | Multifunction \"Crown Complexes\" from Amino Acids and Peptides for Skin and Hair Restoration | BIODERM RESEARCH (US) | 2007-05-03 | — | — | US | claimed |
| CN-117343146-A | Selaginella tamariscina cyclic heptapeptide compound, and preparation method and application thereof | 广西壮族自治区中国科学院广西植物研究所 | 2024-01-05 | — | — | CN | disclosed |
| US-20210161672-A1 | SCAFFOLD WITH ADHESIVE FOR ARTICULAR CARTILAGE REPAIR | HISTOGENICS CORPORATION (US) | 2021-06-03 | — | — | US | disclosed |
| CN-112672717-A | Adhesive-bearing scaffold for articular cartilage repair | 欧酷根公司 | 2021-04-16 | — | — | CN | disclosed |
| EP-3801396-A1 | SCAFFOLD WITH ADHESIVE FOR ARTICULAR CARTILAGE REPAIR | Histogenics Corporation (US) | 2021-04-14 | — | — | EP | disclosed |
| CN-110655557-A | Separation and purification method of pneumocandin B0 serine analogue | 浙江医药股份有限公司新昌制药厂 | 2020-01-07 | — | — | CN | disclosed |
| EP-2010597-B1 | POROUS POLYMER BLEND STRUCTURES | UNIV QUEENSLAND (AU) | 2015-06-17 | — | — | EP | disclosed |
| US-20130267483-A1 | Hydroxy Acid Complexes for Skin Antiaging, Acne, and Skin Whitening | BIODERM RESEARCH (US) | 2013-10-10 | — | — | US | disclosed |
| US-20120189569-A1 | Hydroxy Acid Complexes for Skin Renovation and Clarity | BIODERM RESEARCH (US) | 2012-07-26 | — | — | US | disclosed |
| WO-2012094708-A1 | BONE GRAFT BIOMATERIAL | THE UNIVERSITY OF QUEENSLAND (AU) | 2012-07-19 | — | — | WO | disclosed |
| US-6103255-A | Porous polymer scaffolds for tissue engineering | RUTGERS, THE STATE UNIVERSITY (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0970191-A2 | CYTOCHROME P450 MONOOXYGENASES | Novartis AG (CH) | 2000-01-12 | — | — | EP | disclosed |
| US-5882851-A | DNA MOLECULE CODING FOR A CYTOCHROME P-450 MONOOXYGENASE THAT CATALYZES THE CONVERSION OF AN AMINO ACID TO THE CORRESPONDING N-HYDROXYAMINO ACID AND THE CONVERSION OF SAID N-HYDROXYAMINO ACID TO THE CORRESPONDING OXIME | NOVARTIS FINANCE CORPORATION (US) | 1999-03-16 | — | — | US | disclosed |
| WO-1998040470-A2 | CYTOCHROME P450 MONOOXYGENASES | NOVARTIS AG (CH) | 1998-09-17 | — | — | WO | disclosed |
| EP-0733112-A1 | CYTOCHROME P-450 MONOOXYGENASES | Novartis AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995016041-A1 | CYTOCHROME P-450 MONOOXYGENASES | CIBA-GEIGY AG (CH) | 1995-06-15 | — | — | WO | disclosed |
| US-5310539-A | Paramagnetic rare earth metals, magnetic resonance imaging | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1994-05-10 | — | — | US | disclosed |
| EP-0580734-A1 | MELANIN-BASED AGENTS FOR IMAGE ENHANCEMENT | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1994-02-02 | — | — | EP | disclosed |
| WO-1992018166-A1 | MELANIN-BASED AGENTS FOR IMAGE ENHANCEMENT | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120189569-A1 | Hydroxy Acid Complexes for Skin Renovation and Clarity | CUTA, TYR, RBP4 | SLC7A5 46/4885CA2 2447/4885CAMK2A 2506/4885 |
| US-20130267483-A1 | Hydroxy Acid Complexes for Skin Antiaging, Acne, and Skin Whitening | CUTA, TYR, SLC30A6 | SLC7A5 24/4885CA2 2397/4885CAMK2A 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.